This [Much Less Speculative] Biotech Just Received a Major Tailwind

finviz dynamic chart for  NVO

Novo Nordisk (NVO) is a multinational pharmaceutical company that develops treatments for diseases ranging from diabete to rare blood disorders.

While it’s a much less speculative investment in the biotech market compared to MindMed, the company just received a major growth tailwind.

This week, the U.S. Food and Drug Administration (FDA) approved the company’s long-awaited obesity drug. While companies have touted “magical” weight loss formulas promising incredible results, none have effectively created a drug to “cure” obesity. 

At least, not until Novo Nordisk created Wegovy for chronic weight management. Data released by the company showed that volunteers with type 2 diabetes lose 17% to 18% of their total weight over 68 weeks. That’s significantly higher than the average decline of 5% to 10% from rival drugs. 

And with one-third of the U.S. population suffering from obesity, that means demand for the drug should be incredibly high as it becomes more established on the market.

The Guardian: “New pill could spell the end of aging.”


Take a look at this picture:

This pill is set to completely change the lives of millions of Americans…

And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…

Investors who get in on the ground floor stand to become rich beyond their wildest dreams.

Here are all the details.